Johnson & Johnson Cash on Hand 2010-2024 | JNJ
Johnson & Johnson cash on hand from 2010 to 2024. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
- Johnson & Johnson cash on hand for the quarter ending March 31, 2024 was $22.927B, a 2.9% increase year-over-year.
- Johnson & Johnson cash on hand for 2023 was $22.927B, a 2.9% increase from 2022.
- Johnson & Johnson cash on hand for 2022 was $22.281B, a 29.51% decline from 2021.
- Johnson & Johnson cash on hand for 2021 was $31.608B, a 25.5% increase from 2020.
Johnson & Johnson Annual Cash on Hand
(Millions of US $) |
| 2023 |
$22,927 |
| 2022 |
$22,281 |
| 2021 |
$31,608 |
| 2020 |
$25,185 |
| 2019 |
$19,287 |
| 2018 |
$19,687 |
| 2017 |
$18,296 |
| 2016 |
$41,907 |
| 2015 |
$38,376 |
| 2014 |
$33,089 |
| 2013 |
$29,206 |
| 2012 |
$21,089 |
| 2011 |
$32,261 |
| 2010 |
$27,658 |
| 2009 |
$19,425 |
Johnson & Johnson Quarterly Cash on Hand
(Millions of US $) |
| 2023-12-31 |
$22,927 |
| 2023-09-30 |
$23,511 |
| 2023-06-30 |
$28,505 |
| 2023-03-31 |
$32,308 |
| 2022-12-31 |
$22,281 |
| 2022-09-30 |
$34,079 |
| 2022-06-30 |
$32,568 |
| 2022-03-31 |
$30,388 |
| 2021-12-31 |
$31,608 |
| 2021-09-30 |
$31,001 |
| 2021-06-30 |
$25,306 |
| 2021-03-31 |
$24,619 |
| 2020-12-31 |
$25,185 |
| 2020-09-30 |
$30,781 |
| 2020-06-30 |
$19,135 |
| 2020-03-31 |
$18,024 |
| 2019-12-31 |
$19,287 |
| 2019-09-30 |
$17,945 |
| 2019-06-30 |
$15,278 |
| 2019-03-31 |
$15,336 |
| 2018-12-31 |
$19,687 |
| 2018-09-30 |
$19,364 |
| 2018-06-30 |
$18,139 |
| 2018-03-31 |
$15,204 |
| 2017-12-31 |
$18,296 |
| 2017-09-30 |
$16,231 |
| 2017-06-30 |
$12,853 |
| 2017-03-31 |
$39,343 |
| 2016-12-31 |
$41,907 |
| 2016-09-30 |
$40,433 |
| 2016-06-30 |
$42,584 |
| 2016-03-31 |
$39,855 |
| 2015-12-31 |
$38,376 |
| 2015-09-30 |
$37,306 |
| 2015-06-30 |
$33,954 |
| 2015-03-31 |
$31,319 |
| 2014-12-31 |
$33,089 |
| 2014-09-30 |
$33,005 |
| 2014-06-30 |
$31,624 |
| 2014-03-31 |
$29,392 |
| 2013-12-31 |
$29,206 |
| 2013-09-30 |
$25,228 |
| 2013-06-30 |
$25,129 |
| 2013-03-31 |
$21,668 |
| 2012-12-31 |
$21,089 |
| 2012-09-30 |
$19,771 |
| 2012-06-30 |
$16,915 |
| 2012-03-31 |
$33,847 |
| 2011-12-31 |
$32,261 |
| 2011-09-30 |
$30,927 |
| 2011-06-30 |
$29,682 |
| 2011-03-31 |
$26,867 |
| 2010-12-31 |
$27,658 |
| 2010-09-30 |
$22,126 |
| 2010-06-30 |
$18,901 |
| 2010-03-31 |
$18,010 |
| 2009-12-31 |
$19,425 |
| 2009-09-30 |
$14,337 |
| 2009-06-30 |
$14,716 |
| 2009-03-31 |
$13,933 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$357.925B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
